The consolidation of poultry since the 1950s largely depended upon two primary management tools: vaccination and antibiotics. These two tools allowed for the prevention of both bacterial and viral infections that could greatly impact poultry raised in large numbers. Antibiotics were also found to improve poultry growth and feed efficiency over 10% when fed below therapeutic levels. Hence, by the late 1950s, the use of antibiotics for improving growth and feed efficiency in consolidated poultry flocks was commonplace. Early in the discovery of antibiotics, the development of resistance was always a concern, particularly in humans' consuming animal products that were fed antibiotics. While science never conclusively supported this concern, advocate groups persuaded users of poultry products to avoid foods derived from animals fed antibiotics. Scientists studied the theories supporting the mechanism(s) by which antibiotics improve growth. Products to improve animal performance in the absence of antibiotics have included: enzymes, competitive microbial species, precolonization of the gastrointestinal tract with favorable microbial species, and dietary additives that inhibit microbial attachment to the intestinal mucosa. A recent addition to dietary substances that improve growth and feed efficiency in poultry and other species are egg antibodies that specifically target processes involved in the immune regulation of growth. Antibodies to neuropeptides and the rate-limiting enzyme, phospholipase A 2 , in eicosanoid synthesis are presented, along with the hypothesized mechanism of action. Evidence suggested that egg antibodies offer a new strategy in improving the efficiency of animal performance.
INTRODUCTION
The ecosystem of the poultry house is a rich study of the interface among the vertebrate, the microbe, and the overwhelming environmental conditions that govern animal and microbial interplay. The intense interaction between the kingdoms Animalia and Monera in the confines of the poultry house, or any other intensively raised agriculturally relevant species, provides 1 To whom correspondence should be addressed: mcook@wisc.edu. a unique opportunity to explore human intervention in the natural relationships and dynamics of diverse living organisms. The ecosystem of the poultry house and modern management of it offer scientists a unique setting to discover developmental strategies of species living in confined cohabitation.
The gastrointestinal tract of the avian, or for that matter any animal species regardless of the environment and imposed managerial practices, represents the stage upon which the animal must cope, benefit, and defend against its microbial neighbor. Estimates have been made that the bacterial component to the weight of an animal, particularly in the gastrointestinal tract, is 1 to 2% of the animal's weight [1, 2] . The symbiotic role between this microbial mass and the fowl has an evolutionary function that can not be denied, but in the intensive environment in which poultry are raised today, in light of human intervention, one should question its value in modern agriculture.
The discovery and use of antibiotics and vaccination in animal agriculture have evolved from the management of small poultry flocks in the era prior to1890s [3] to the large consolidated units of today [4] . The current state of antimicrobial use in animal agriculture suggests that "continual and fearless sifting and winnowing by which alone the truth can be found" [5] must be renewed by scientists studying the ecosystem of the poultry house.
ORIGINS OF ANTIBIOTICS IN ANIMAL HUSBANDRY
The topic of microbial resistance to antibiotics began soon after their discovery and before their commercial use. Scientists have always challenged the commercial use of antibiotics in animal agriculture. While the debates have raged over the quality of the science supporting or banning the growth-promoting use of antibiotics in animal husbandry, recent history suggests that the arguments for or against an antibiotic ban are academic. If resistant microbial populations are the outcome of antibiotic use in poultry, the industry will stop using them due to fundamental economics. If the consumer is willing to pay for any added cost of antibiotic-free animal products, whether based on science or the result of advocacy, the industry will supply antibioticfree products. Numerous papers have been published on the value of antibiotics to society and implications of their use in animal feeds. Historical justification for the use of antibiotic in animal feeds [6] and evidence for an antibiotic ban in animal feeds continues to be based on poor science. We have moved beyond an era that scientific justification is accepted as a sole reason for using a given practice. To the marketer of a poultry product, science lags far behind social opinion, market force, purchase power, and consumer use in the decision process.
No greater triumphs in modern medicine have occurred than the discovery of vaccination and antibiotics. Vaccination allowed us to move beyond the scourge of viral infections, and antibiotics treat the bacterial diseases. With these 2 modern technological advances implemented in modern animal agriculture, the industry changed, and great efficiency in food production was realized.
President Herbert Hoover's prediction of "a chicken in every pot, and a car in every garage" [7] preempted the use of antibiotics in consolidating the poultry industry (the stock market crash of 1929 and the beginning of the depression occurred shortly after his platform), and hence prosperity fulfilled his prediction. Perhaps, the discovery of antibiotics was as critical to prosperity as was the war.
As with antibiotics and so many other scientific discoveries, a typical period between discovery and commercial use is over a decade. Ernest Duchesne (1896, Germany) was the first to provide evidence of an antibacterial substance. However, its rediscovery was not again recognized until Flemming (1928, England), after a weekend vacation, noted that a mold on his agar plates had lytic activity to his Staphylococcus cultures. Penicillium mold was cultured, but the antimicrobial compound was not fully isolated. It was not until 1941 (Florey, Chain, Fletcher, Gardner, Heatly, and Jennings) that the potential use of the antimicrobial from Penicillium cultures was first realized [8] . Welch and Marti-Ibanez [8] described the first positive response to penicillin in a terminal patient in London. While the use of penicillin in this human experiment demonstrated many signs of improvement resulting from staphylococcal infection, the patient later died when the experimenters ran out of the crude extract [8, 9] .
The microbial discoveries in the world continued to reveal new compounds to treat and prevent bacterial infections. Selman Waksman in 1943 [8, 10 ] discovered streptomycin and its use for treating tuberculosis. His patents went on to be considered among the top 10 patents that influenced the world. In 1945, Waksman coined the term "antibiotic" [8] .
The implementation of antibiotics in treating human infectious bacterial diseases was rapidly followed by the treatment of animal diseases. Moore et al. in 1946 [11] showed that streptomycin improved growth in chicks. The growth promoting value of this work was overlooked. Meanwhile, T. Jukes joined Lederle Laboratories (NY) in 1942. In his studies involving fermentation methods to make vitamin B12, a cofermentative factor, chlorotetracycline (trade name, Aureomycin), was discovered [12] . This discovery, along with previous research on vaccination, provided the final pieces to allow the rapid consolidation of poultry industries and the realization of Hoover's 1928 presidential platform [13] .
As early as 1945, Flemming and others reported that microbial resistance to antibiotics was a serious concern with regard to their use. Within 10 yr of antibiotic use in humans, resistance to penicillin was reported to exceed over 50% of hospital patients [9] .
MECHANISMS OF ANTIBIOTIC ACTION
Antibiotic use in animal feeds and as antimicrobial therapy for disease continued to grow beginning in 1951 [14] . Dafwang reported that the total antibiotic use in animal feeds approached 50% of the total amount synthesized in 1978 [15] . These numbers appear to be in contrast to the Animal Health Institute [16], which suggested that the level of use may be lower. Witte [17] reported that in Denmark in 1994, only 0.1% of vancomycin entering the country was used for humans, and the remainder was used for animal agriculture. In Australia, 2 antibiotics with a similar mode of action, vancomycin and avoparcin, when combined, 99% of the antibiotics was used for animal feeds, and 1% was designated for human therapy [17] . Hence, much confusion remains in published statistics on the actual use of antibiotics for human and animal purposes. However, the animal use of antibiotics appears to be a significant part of the market.
As the use of antibiotics in animal feeds increased soon after their discovery, scientists soon attempted to explain the mechanism by which antibiotics enhanced growth. Postulated mechanisms for improved animal performance, in the absence of overt infectious bacterial diseases, were numerous [6, 14] . Antibiotics were shown very early to have no growth-enhancing effects in the absence of normal microbial intestinal flora. In a study by Levs and Forbes [18] , dietary antibiotics offered no growth-promoting activity in germ-free conditions. The exposure of chicks to bacteria decreased body weight by 11% when compared with chicks raised in a germ-free environment. Improved growth in the presence of bacteria was 7%, if antibiotics were also fed. Clearly the value of improved growth resulting from feeding antibiotics was evident from these early studies. Strategies were identified early and repeated later that would improve animal performance in the absence of antibiotics. Roura et al. [19] showed that increased sanitation of broiler facilities could offset the benefit of using dietary antibiotics to improve animal growth and feed efficiency. Increasing the floor space given per broiler by more than 2.5-fold was also shown to eliminate the benefits of using dietary antibiotics [20] .
Doubling the infrastructure to raise the modern day broiler or attempting to mimic a disinfected environment were not feasible management techniques in improving the animal's efficiency to a level observed with dietary antibiotics. Also at risk of not realizing the efficiencies achieved with antibiotics was maintaining a global advantage in the meat food market place and the cost of animal products. In addition to the above cost, increased use of natural resources, labor cost, and environmental concerns would limit the use of sanitation and increased floor space to maintain productivity without the use of antibiotics.
A clear understanding of how sanitation and decreased density improved animal growth without the use of antibiotics has been discussed in detail. Readers should refer to previous publications [4, 21, 22, 23, 24, 25] . Underlying mechanism of how antibiotics, sanitation, and density affect animal growth, and the physiological and immunological mechanisms have been explained previously [26, 27] .
ANTIBIOTIC RESISTANCE
Resistance of microbes to antibiotics was well recognized soon after they were discovered (see above). The debate over the human health hazard involving the use of antibiotics in animal feeds for the purpose of improving animal performance rages on and is nothing new. Neither side of the argument for or against the use of antibiotics to improve animal efficiency has provided a strong enough argument to settle the debate. Clearly, if the use of antibiotics were such a problem in animal feeds, as has been described by the proponents for the "ban of their use, humankind would be today as susceptible as the London police officer when infected with Staphylococcus in 1941 [8] . Instead of arguing about the issue of resistance, perhaps we should accept it.
Witte [17] described the use of antibiotics in a longitudinal study in eastern Germany that best exemplifies the role of antibiotics in human risk. In a small community, noureseothricin was introduced to improve pig performance in 1983. Prior to its introduction, no resistant bacteria were found to noureseothricin. The antibiotic was fed to improve swine growth from 1983 to 1990. During this period, the microorganisms in the animals and the people of the community were monitored for resistance to the antibiotic. Also during this period, nouresothricin was not used in human therapy.
By 1985, resistant Escherichia coli was found in the intestine and meat of the antibiotic fed pigs. In 1987, resistance to noureseothricin was found in the human pathogen, Shigella (not a swine pathogen). Escherichia coli resistance to the antibiotic was found in pig farmers and the people in the community by 1990. This type of longitudinal study is absent from much of the literature on both sides of the argument for or against the use of antibiotics in animal production. Instead, trace-back and epidemiological studies [28, 29] have played a major role in policy making in the United States with regard to antimicrobial use. These studies [28, 29] have probably served best as teaching documents on the discernment of scientific literature rather than as documents for policy making.
The lack of solid science showing a relationship between feeding antibiotics to animals and bacterial resistance in humans is not due to the lack of talent of scientists around the world, but the short sightedness of funding for the types of projects needed to support such science. Over 50 yr have passed, and the answer is as clear as it was in 1945, with the overwhelming observation that people are not succumbing to the same bacterial infections prior to antibiotic use in animal agriculture, as our most compelling evidence. Long-term, longitudinal research investments, such as 10 to 20 yr of study, are needed to determine the real effects of animal antibiotic feeding on human health.
The current issue on the use of antibiotics in animal feeds is no longer centered on the science of whether or not antibiotics use in animal feeds is a harm to humans, the issue is the market. A chicken is in every pot, and 2 or 3 cars are in every garage. The public is well fed, and now they are looking beyond food, shelter, and water, and basic needs. As scientists, we know better than to ignore the basic needs of mankind. Scientists see beyond the enterprise of human want and desire. When properly funded, the science will be available when society's wants become needs again.
Antibiotics use in animal feeds originated from a need to efficiently feed humankind. However, when the needs of humans for low-cost, abundant, and nutritious foods were met, advocacy groups demanded that food companies be "committed to social responsibility" second to "emerging science" [30] . Hence, the needs of the people were replaced by social wants and not by science. The consequence of a ban on the use of antibiotics for improving animal performance when based on social appeal rather than science can best be studied from the Danish antibiotic ban [31] .
The early decision on the use of antibiotics in animal feeds is worthy of classical systems thinking [32] . While the benefits were "a chicken in every pot and a car in every garage," every change in a management strategy has unintended consequences (see the pheasant example under Consolidation in page 98 of Cook, 2000 [4] ). Unintended consequences of feeding antibiotics to animals as well as their removal as a management strategy should now be given careful thought. Table 1 shows the consequences of a ban or continued use of antibiotics for improved animal production efficiency. What remains clear, however, is "industrial investment in alternatives to antimicrobials for animal growth promotion should...[protect] the fragile resources 
that are critical to successful management of human infectious disease" [17] .
ALTERNATIVES TO ANTIBIOTICS FOR IMPROVED ANIMAL GROWTH
As previously mentioned, scientists do not focus on the wants of the populous but their needs. In fact, in the area of biological science, we have no skills in meeting wants of people. However, we are faced with the balance between the consumer of the product with which our science focuses and with the needs of production to meet both needs and wants, knowing all the while in today's surplus, wants far exceed needs.
Consumers will not pay more for chicken meat unless packed in a manner that is to their advantage. Consumers will not pay for health, environment, conservation, welfare, food safety, or any other advocate agenda item. Consumers may expect these items, but only a very small fraction will pay for them. Science must develop food-related technologies that improve human health and safety, promotes conservation, and environmental sustainability.
In animal agriculture, novel methods to improve efficiency of meat production must be developed if antibiotic use decreases. Hence, any improvements, which will serve as a replacement for antibiotics in animal feed, must enhance growth, improve feed efficiency, or decrease mortality at no additional cost to the consumer.
A number of strategies have been developed to improve animal productivity beyond the traditional nutrient formulation. All of these strategies seek to use natural methods to obtain results achieved by the feeding of antibiotics based upon some fundamental mechanism of antibiotics. There is no question that dietary enzymes have become a very useful product in animal diets. Depending on the nature of the basal ingredients in a diet, responses achieved with dietary enzymes can be quite dramatic. Increased use of enzymes in animal feeds will continue as efficiency becomes more essential in animal production. Several microbial intervention technologies have been developed in an attempt to replace 1 microbial species with another. While the principle of this technology is based on a recognized theory of exclusion, broad use of this technology has not been widespread in the US meat animal industries. Continued definition of uses and limitations and improved technologies for producing cost-effective products still offer promise for these products. With some of these products, there is also preliminary data that suggest improved animal and human health. The latter is unlikely to justify their use in animal feeds. Nutritional strategies to provide nutrients for growth of favorable microflora have also been proposed. More recently, natural substances, which prevent the adherence of select microflora (microbial adherence inhibitors), have been reported as a method of improving animal production efficiency [33] . Clearly, the scientific community and allied industries have invested significantly in the discovery of alternatives to antibiotics. These technologies will require repeated experimentation and testing by poultry and swine users as these technologies improve.
Antibodies
Beginning in the early 1980s, we became interested in the use of antibodies as a means of enhancing growth. At the time, the only largescale means for antibody production appeared to be egg yolk antibodies. Historically, nonfood uses of eggs were based upon physical and nutritive value. Most of these nonfood uses were largely replaced with new technologies, such as adhesives, media, shampoo, and purified proteins. This latter use, purified proteins, suggested that the egg had tremendous value. Using a Sigma Chemical catalog (St. Louis, MO), we calculated the value of a select group of pure proteins found in an egg (Table 2) .
For a laboratory setting, the egg is a rich source of high-value proteins that have specific and unique biological functions. Attempts have been successfully made on the commercial use of select egg proteins. For example, avidin, due to its affinity for binding biotin, is commonly used in immunological-based bioassays. Lysozyme now sells for approximately US$150/kg. When added at a level of 0.3 g/liter to white or red wine, microbial stability is improved, and a reduction in the amount of sulfite, as a stabilizer, is needed [34] .
The commercial use of lysozyme represents an example of added value to an egg, even though the market value of the product, when sold in mass quantities, is much less than shown in Table 2 . However, the fraction of select egg proteins for purposes other than their current intended use as a food, could greatly improve the value of an egg product.
Egg antibodies are also a valued egg protein for both laboratory and commercial use. The ability to change the binding specificity of an antibody by a mere vaccination procedure provides an unlimited array of antibodies with capacity to recognize virtually any epitope. Commercial companies and animal units on campuses currently provide egg antibody synthesis for laboratory needs (see [35] for an example). All universities that maintain a flock of laying hens should offer, for a fee, this service for their scientists as an alternative method for generating antigen-specific antibodies.
The question we proposed in the early 1980s, while providing this service at the University of Wisconsin-Madison, was if 45 tons of antigenspecific antibody could be generated per year for a commercial use, what antigen would it be targeted toward? In Table 3 , we estimated the market potential for an egg antibody of high demand for an end use. One potential high value use of eggs as a source of antibodies could increase the demands for laying hens in the United States by 10 to 100%.
Egg Antibodies to Improve Growth and Feed Efficiency in Animals. Beginning in the mid 1980s, our work initially focused on the generation of egg antibodies in the breeding hen that could be passively transferred to the progeny, by way of the yolk, to enhance progeny productivity. Passively transferred antibody to urease was found to enhance progeny growth and feed efficiency [36, 37] . This work was based on the studies of Visek at the University of Illinois, who had demonstrated that ammonia production in the gastrointestinal tract limited animal performance [38] . While this work appeared promising, other targets were soon identified.
Studies involving passively transferred antibodies were stopped early in our work since the technique required handling individual breeders throughout their reproductive life for repeated injections. Methods to control the titer of passively transferred antibody and the short duration of their effects (first 3 wk of life) limited the value of this approach. Hence, the objective was to develop an egg antibody that could be fed to animals that could enhance the efficiency of meat animal production. The second major objective was to obtain patents to improve the likelihood of commercialization. While discussed in more detail elsewhere [39, 40, 41, 42] antibodies directed to prevent immune-induced wasting were selected as the targeted mechanism [19, 26, 27] .
Antineuropeptide Antibodies. Klasing et al. had shown that the growth suppression and anorexia of immune stimulation were the direct result of the release of select cytokines, such as Interleukin-1 (IL-1) [43] . They also showed that when IL-1 was directly incubated with skeletal muscle, decreased muscle synthesis and in- Experimental design is similar to that described in Table  4. C Weight gain over control is the percent-improved body weight gain (0 to 3 wk) of chicks fed dried egg yolk powder from hens vaccinated with neuropeptide Y conjugated to bovine gamma globulin. Control fed chicks had no antibody to neuropeptide Y. Points of feed conversion = hundredths of kilograms of less feed per kilogram gain when compared with control-fed chicks.
creased muscle degradation was induced. Similar results were also reported in other research involving mammals [44, 45, 46] . Egg antibodies are not absorbed when supplemented in the diet; hence, target epitopes for preventing the decline of performance associated with conventional housing [18] had to be associated with an epitope that was luminally exposed in the intestine. Two works suggested that IL-1 was involved in the anorexia associated with immune stress [47, 48] . These works suggested that IL-1 was responsible for the release of a neuropeptide, cholecystokinin (CCK), which in turn decreased appetite during immune stimulation. Rao [49] had shown that neuropeptides are released into the intestinal lumen. Hence, it was hypothesized that animals fed antibody to the CCK peptide would have increased growth due to enhanced appetite (Figure 1) . During an immune challenge, the macrophage would release IL-1, which was essential for the proliferation of antigen specific immune reactive cells. Interleukin-1 would also direct systemic physiological changes, such as muscle wasting [22, 26, 27, 43] and anorexia due to the release of neuropeptides [47, 48] . Fed egg antibodies to these neuropeptides (i.e., CCK) would bind the neuropeptides in the intestinal lumen and thereby improve animal performance.
Antibodies to numerous neuropeptides were made and fed to broiler chicks to assess growth rates and feed efficiency under conventional environments. Antibodies to both CCK (Table 4) and neuropeptide Y (aneuropeptide Y; Table 5 ) improved broiler chick performance. The basic mechanism of this improved performance was never determined but seemed to be unrelated to the regulation of feed intake [41, 42] . Commercialization of the antineuropeptide technology is currently being accomplished by Arkion Life Sciences, LLC (formally, DCV Biologics) [50] .
Antiphospholipase A 2 Antibodies. In studies unrelated to the egg antibody technology, we were actively studying immune-induced growth depression caused by IL-1 and tumor necrosis factor. These investigations [4, 21, 22, 23, 24, 25] suggested that the regulation of eicosanoid production was a mechanism to prevent immune-induced decreased performance. While initial work focused on the systemic regulation of growth depression caused by immune challenge, another antigen for targeted antibody synthesis became evident.
A physiological effect of feeding antibiotics is decreased intestinal weight and thickness [14] . Increased thickness or weight of the intestine in conventionally raised chickens when compared with those raised in germ-free conditions could largely be attributed to accumulated immune defenses directed toward intestinal bacteria in the lumen of the intestine (Figure 2 ). The cost of maintaining this intestinal immune surveillance was hypothesized to be decreased rates of gain and feed efficiency. A reduction of immune stimulating intestinal microflora by using dietary antibiotics, increased sanitation, or reduced flock density (above) would, in turn, reduce the immune challenge between the gastrointestinal microflora and the mucosal barrier (hence, the intestinal immune defense). This would, in turn, result in decreased intestinal thickness and improved growth and feed efficiency that approached conditions realized in germ-free environments (Figure 3) .
If the ecosystem of the broiler house were stable, generation after generation of genetic selection of animals for performance in immunestimulating environments would be governed by the model presented in Figure 3 . However, not only are the microbes changing in the ecosystem of the broiler house, particularly due to management strategies that improve animal growth and feed efficiency, but also the animal is changing with each subsequent generation [4] . We hypothesized that genetic selection for growth and feed efficiency was also having a negative impact on immune performance. Using an elite line of duck grandparents, we investigated the relationship between body weight and cell-medi- 3. Proposed mechanism by which antibiotics stimulate animal performance. In the absence of gastrointestinal bacteria due to the feeding of antibiotics, the need to recruit immune cells to the intestine is reduced; hence, animal performance (output) is improved. FIGURE 4. The correlation between body weight and cell-mediated immunity index (CMI) in an elite line of breeding ducks undergoing selection for improved body weight gain (unpublished data). A grandparent population, used for selection, were bled, and lymphocyte blastogensis to concavalin A was assessed. The correlation, −0.38 was significant (P < 0.05). ated immunity (measured by mitogen-induced blastogensis). Ducks with the greatest body weight in a given population and generation had the poorest relative cell-mediated immunity (Figure 4) . These results suggested that improved animal performance could be achieved by either decreasing the amount of immune stimulation (i.e., sanitation, decreased density, or by use of dietary antibiotics) or by immune suppression (decreased inflammation; Figure 5 ).
Studies involving conjugated linoleic acid (CLA) had suggested that one of the mechanisms by which CLA had so many biological effects on animal health was through the eicosanoid pathway [24, 25] . Hence regulation of the eicosanoid pathway at an intestinal level was hypothesized as a mechanism to reduce immune-induced gut wall thickening (inflammation) and thereby enhance animal performance. Eicosanoids can be proinflammatory and were believed to be involved in the animal's response to a conventional environment. The precursor for eicosanoid production is arachidonic acid in the sn-2 position of phospholipids in the cell membrane. Upon response to certain stimuli, phospholipase A 2 (PLA 2 ) cleaves arachidonic acid from the phospholipids where it is converted to prostaglandins or leukotrienes by action of the cyclooxygenase or lipoxygenase pathways. In turn, the released eicosanoids can recruit inflammatory cells to the site of their release (hence, gut wall thickening). Microbes have also evolved to release their own forms of PLA 2 . Microbial PLA 2 was believed to be a mechanism by which microbes gain access into the animal (invasive factor). Hence, it was hypothesized ( Figure 6 ) that egg antibody directed toward PLA 2 would improve animal growth and feed efficiency when the antibody was fed to conventionally housed animals [51, 52] . This technology is currently being developed by August LLC in Madison, Wisconsin.
Antibody was made to a variety of PLA 2 sources in laying hens. Eggs were collected, dried, and fed to broiler chicks in a series of 3-wk battery trials. Table 6 summarizes the results of improved performance when chicks were fed antibody to PLA 2 .
Antibacterial Antibodies. A number of other strategies to use egg antibodies to improve animal growth and development have been developed. GHEN Corporation [53] and Nutreco [54] have developed egg antibody products that specifically target select microorganisms in the gut mucosa. These products are designed to improve overall gut health which in turn improves animal growth and feed efficiency.
WHY EGG ANTIBODIES?
Hein [55] provides an excellent review on the use and need for antibodies in human therapy. Their preferred method of antibody synthesis for pharmaceuticals is by the use of transgenic plants. While this technology will be cost effective for monoclonal antibodies for human systemic use, it is unlikely to compete with the laying hen for products mentioned above. The hen offers many advantages for the production of antibodies. The polyclonal nature of the antibody allows one to rapidly proceed in developing an effective antibody for a use without defining the epitope of importance. Gene arrangement identification, insertion, and cloning would be necessary for antibody synthesis using crops or fermentation. Hence the time, labor, and input cost to realize an effective product is much more rapid using the laying hen. The technical skill and infrastructure to produce egg antibodies already exist. The only limitation is FIGURE 6 . Proposed mechanism by which dietary egg yolk antibody to phospholipase A 2 (aPLA 2 ) improves animal growth and feed efficiency. Dietary aPLA 2 binds both microbial (mPLA 2 ) and mucosal cellular (cPLA 2 ) PLA 2 , preventing the cleavage of arachidonic acid from the sn-2 position of mucosal phospholipids, whereupon it can be enzymatically converted to inflammatory eicosanoids.
to identify the targeted antigen and demonstrate efficacy. Regulatory issues favor the use of egg antibody technology. Antibodies are naturally found in many of the animal foods that we currently eat, if not destroyed by food processing. In addition, humans and animals have a long
